A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism, published as a randomized controlled trial.

This is an open-label prospective randomised controlled trial to compare progression of cardiovascular and chronic kidney disease mineral and bone disorder (CKD-MBD) parameters.

Who Took Part

According to the abstract, 36 patients were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults.

Patients were randomised to receive cinacalcet alongside standard therapy or standard therapy alone.

Following randomization, all 36 patients underwent an intensive 12-week period of bone disease management aiming for iPTH 150-300 pg/mL.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The patients were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

Being open-label, the Parathyroid Hormone (PTH 1-84) study did not mask who received what.

The primary outcome was change in vascular calcification using CT agatston score.

Secondary outcomes included pulse wave velocity (PWV), left ventricular mass index (LVMI), carotid intima-media thickness (CIMT), augmentation index (Aix) and bone measurements.

The above measurements were obtained at baseline and 12 months.

What Was Measured

The subject headings attached to it are Calcinosis, Calcium-Regulating Hormones and Agents, Carotid Intima-Media Thickness, Cinacalcet, Heart Ventricles, Hyperparathyroidism, Secondary and Kidney Failure, Chronic.

Author keywords: Chronic kidney disease-mineral bone disorder (CKD-MBD), Left ventricular mass index (LVMI), Parathormone (PTH) and Secondary hyperparathyroidism.

What This Means in Plain Language

The paper is a randomized and open-label study of Parathyroid Hormone (PTH 1-84) in 36 patients in people with hyperparathyroidism.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (BMC nephrology), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.